Woodline Partners LP Editas Medicine, Inc. Transaction History

Woodline Partners LP

$11 Billion
Q3 2024

A detailed history of Woodline Partners LP transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 900,421 shares of EDIT stock, worth $1.09 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

900,421

Previous 970,491 7.22%

Holding current value

$1.09 Million

Previous $4.53 Million 32.26%

% of portfolio

0.03%

Previous 0.05%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.39 - $5.96 $237,537 - $417,617	-70,070 Reduced 7.22%	900,421 $3.07 Million
Q2 2024 Aug 14, 2024	BUY	$4.67 - $7.28 $352,542 - $549,574	75,491 Added 8.43%	970,491 $4.53 Million
Q1 2024 May 15, 2024	SELL	$7.03 - $11.07 $2,819 - $4,439	-401 Reduced 0.04%	895,000 $6.64 Million
Q4 2023 Feb 14, 2024	SELL	$6.25 - $11.11 $14.8 Million - $26.3 Million	-2,364,309 Reduced 72.53%	895,401 $9.07 Million
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $3.53 Million - $4.75 Million	510,405 Added 18.56%	3,259,710 $25.4 Million
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $653,076 - $1.18 Million	102,685 Added 3.88%	2,749,305 $22.6 Million
Q1 2023 May 15, 2023	BUY	$7.03 - $11.53 $3.99 Million - $6.55 Million	567,872 Added 27.32%	2,646,620 $19.2 Million
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $17.3 Million - $27.5 Million	2,078,748 New	2,078,748 $18.4 Million
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $9.93 Million - $21.2 Million	994,020 Added 4346.2%	1,016,891 $12 Million
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $322,023 - $631,925	22,871 New	22,871 $435,000

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $83.2M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Editas Medicine, Inc. Transaction History